Valuation UCB

Stocks

Market Closed - Euronext Bruxelles 11:55:00 2026-11-11 EST			5-day change	1st Jan Change
291.30 ^EUR	-1.09%		+3.08%	+22.09%

11-09	UCB Announces Week 24 Data For BIMZELX Bimekizumab-Bkzx From BE BOLD Study	CI
11-09	UCB And Biogen Announce Clinical Profile Data For Dapirolizumab Pegol In Systemic Lupus Erythematosus	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	18,947	13,973	14,969	36,464	45,333	55,540	-	-
Change	-	-26.25%	7.12%	143.6%	24.32%	22.52%	-	-
Enterprise Value (EV) ¹	19,807	15,973	17,146	37,918	45,326	55,662	53,326	50,581
Change	-	-19.36%	7.34%	121.15%	19.54%	22.8%	-4.2%	-5.15%
P/E	17.9x	33.4x	44.8x	34.3x	29.1x	24.8x	21.6x	18.2x
PBR	2.32x	1.58x	1.67x	3.64x	4.18x	4.46x	3.85x	3.14x
PEG	-	-0.6x	-2.2x	0x	0.6x	0.6x	1.5x	1x
Capitalization / Revenue	3.28x	2.53x	2.85x	5.93x	5.86x	6.14x	5.53x	4.99x
EV / Revenue	3.43x	2.9x	3.26x	6.16x	5.86x	6.15x	5.31x	4.55x
EV / EBITDA	12.1x	12.7x	12.7x	25.7x	17.2x	16.2x	13.5x	11.1x
EV / EBIT	15x	23.7x	26.1x	45.4x	22.6x	19.6x	16.3x	12.9x
EV / FCF	15.6x	18.4x	38.5x	41.2x	24.6x	24.4x	18.4x	14.9x
FCF Yield	6.42%	5.43%	2.6%	2.43%	4.06%	4.09%	5.44%	6.7%
Dividend per Share ²	1.3	1.33	1.36	1.39	1.45	1.457	1.502	1.534
Rate of return	1.3%	1.81%	1.72%	0.72%	0.61%	0.5%	0.52%	0.53%
EPS ²	5.6	2.2	1.76	5.61	8.2	11.74	13.47	15.99
Distribution rate	23.2%	60.5%	77.3%	24.8%	17.7%	12.4%	11.2%	9.59%
Net sales ¹	5,777	5,517	5,252	6,152	7,741	9,051	10,049	11,122
EBITDA ¹	1,641	1,260	1,349	1,476	2,636	3,441	3,962	4,571
EBIT ¹	1,318	675	657	836	2,009	2,847	3,280	3,907
Net income ¹	1,058	418	343	1,065	1,558	2,273	2,590	3,056
Net Debt ¹	860	2,000	2,177	1,454	-7	121.9	-2,214	-4,959
Reference price ²	100.35	73.56	78.90	192.20	238.60	291.30	291.30	291.30
Nbr of stocks (in thousands)	188,812	189,959	189,721	189,720	189,996	190,663	-	-
Announcement Date	2/24/22	2/22/23	2/28/24	2/27/25	2/24/26	-	-	-

¹EUR in Million²EUR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
UCB	25.09x	6.22x	16.35x	0.49%	62.61B
ELI LILLY AND COMPANY	41.91x	14.16x	30.08x	0.48%	1,276B
JOHNSON & JOHNSON	41.09x	6.89x	19.39x	1.9%	676B
ABBVIE INC.	37.85x	8.58x	17.73x	2.35%	519B
ROCHE HOLDING AG	21.6x	5.24x	13.12x	2.49%	388B
MERCK & CO., INC.	105.09x	5.99x	25.53x	2.29%	365B
NOVARTIS AG	23.85x	5.92x	14.34x	2.69%	307B
ASTRAZENECA PLC	24.15x	4.85x	13.63x	1.8%	287B
AMGEN INC.	24x	7.37x	13.6x	2.17%	252B
GILEAD SCIENCES, INC.	-40.15x	7.43x	46.76x	1.93%	212B
Average	30.45x	7.27x	21.05x	1.86%	435B
Weighted average by Cap.	37.06x	8.85x	22.50x	1.67%